|
1
|
van Meerbeeck JP, Fennell DA and De
Ruysscher DK: Small-cell lung cancer. Lancet. 378:1741–1755. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Horn L, Mansfield AS, Szczęsna A, Havel L,
Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio
M, et al: First-line atezolizumab plus chemotherapy in
extensive-stage small-cell lung cancer. N Engl J Med.
379:2220–2229. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N,
Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH,
et al: Durvalumab plus platinum-etoposide versus platinum-etoposide
in first-line treatment of extensive-stage small-cell lung cancer
(CASPIAN): A randomised, controlled, open-label, phase 3 trial.
Lancet. 394:1929–1939. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kim YH, Goto K, Yoh K, Niho S, Ohmatsu H,
Kubota K, Saijo N and Nishiwaki Y: Performance status and
sensitivity to first-line chemotherapy are significant prognostic
factors in patients with recurrent small cell lung cancer receiving
second-line chemotherapy. Cancer. 113:2518–2523. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk
Y, Cuceviá B, Juhasz G, Thatcher N, Ross GA, Dane GC and Crofts T:
Phase III trial comparing supportive care alone with supportive
care with oral topotecan in patients with relapsed small-cell lung
cancer. J Clin Oncol. 24:5441–5447. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
von Pawel J, Schiller JH, Shepherd FA,
Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer
MC, Depierre A, et al: Topotecan versus cyclophosphamide,
doxorubicin, and vincristine for the treatment of recurrent
small-cell lung cancer. J Clin Oncol. 17:658–667. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Eckardt JR, von Pawel J, Pujol JL, Papai
Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G and Ross G:
Phase III study of oral compared with intravenous topotecan as
second-line therapy in small-cell lung cancer. J Clin Oncol.
25:2086–2092. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jotte R, Conkling P, Reynolds C, Galsky
MD, Klein L, Fitzgibbons JF, McNally R, Renschler MF and Oliver JW:
Randomized phase II trial of single-agent amrubicin or topotecan as
second-line treatment in patients with small-cell lung cancer
sensitive to first-line platinum-based chemotherapy. J Clin Oncol.
29:287–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
von Pawel J, Jotte R, Spigel DR, O'Brien
ME, Socinski MA, Mezger J, Steins M, Bosquée L, Bubis J, Nackaerts
K, et al: Randomized phase III trial of amrubicin versus topotecan
as second-line treatment for patients with small-cell lung cancer.
J Clin Oncol. 32:4012–4019. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Inoue A, Sugawara S, Yamazaki K, Maemondo
M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, et
al: Randomized phase II trial comparing amrubicin with topotecan in
patients with previously treated small-cell lung cancer: North
Japan lung cancer study group trial 0402. J Clin Oncol.
26:5401–5406. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Horita N, Yamamoto M, Sato T, Tsukahara T,
Nagakura H, Tashiro K, Shibata Y, Watanabe H, Nagai K, Nakashima K,
et al: Amrubicin for relapsed small-cell lung cancer: A systematic
review and meta-analysis of 803 patients. Sci Rep. 6:189992016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Goto K, Ohe Y, Shibata T, Seto T,
Takahashi T, Nakagawa K, Tanaka H, Takeda K, Nishio M, Mori K, et
al: Combined chemotherapy with cisplatin, etoposide, and irinotecan
versus topotecan alone as second-line treatment for patients with
sensitive relapsed small-cell lung cancer (JCOG0605): A
multicentre, open-label, randomised phase 3 trial. Lancet Oncol.
17:1147–1157. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wakuda K, Miyawaki T, Miyawaki E, Mamesaya
N, Kawamura T, Kobayashi H, Omori S, Nakashima K, Ono A, Kenmotsu
H, et al: Efficacy of second-line chemotherapy in patients with
sensitive relapsed small-cell lung cancer. In Vivo. 33:2229–2234.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Baize N, Monnet I, Greillier L, Geier M,
Lena H, Janicot H, Vergnenegre A, Crequit J, Lamy R, Auliac JB, et
al: Carboplatin plus etoposide versus topotecan as second-line
treatment for patients with sensitive relapsed small-cell lung
cancer: An open-label, multicentre, randomised, phase 3 trial.
Lancet Oncol. 21:1224–1233. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Murakami H, Yamamoto N, Shibata T, Takeda
K, Ichinose Y, Ohe Y, Yamamoto N, Takeda Y, Kudoh S, Atagi S, et
al: A single-arm confirmatory study of amrubicin therapy in
patients with refractory small-cell lung cancer: Japan clinical
oncology group study (JCOG0901). Lung Cancer. 84:67–72. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ardizzoni A, Hansen H, Dombernowsky P,
Gamucci T, Kaplan S, Postmus P, Giaccone G, Schaefer B, Wanders J
and Verweij J: Topotecan, a new active drug in the second-line
treatment of small-cell lung cancer: A phase II study in patients
with refractory and sensitive disease. The European organization
for research and treatment of cancer early clinical studies group
and new drug development office, and the lung cancer cooperative
group. J Clin Oncol. 15:2090–2096. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kondo R, Watanabe S, Shoji S, Ichikawa K,
Abe T, Baba J, Tanaka J, Tsukada H, Terada M, Sato K, et al: A
Phase II study of irinotecan for patients with previously treated
small-cell lung cancer. Oncology. 94:223–232. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Horiuchi K, Sato T, Kuno T, Takagi H,
Hirsch FR, Powell CA and Fukunaga K: Platinum-doublet chemotherapy
as second-line treatment for relapsed patients with small-cell lung
cancer: A systematic review and meta-analysis. Lung Cancer.
156:59–67. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Saruwatari K, Umemura S, Nomura S, Kirita
K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Ohe Y and Goto K:
Prognostic factor analysis in patients with small-cell lung cancer
treated with third-line chemotherapy. Clin Lung Cancer. 17:581–587.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ready N, Farago AF, de Braud F, Atmaca A,
Hellmann MD, Schneider JG, Spigel DR, Moreno V, Chau I, Hann CL, et
al: Third-line nivolumab monotherapy in recurrent SCLC: CheckMate
032. J Thorac Oncol. 14:237–244. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Spigel DR, Vicente D, Ciuleanu TE,
Gettinger S, Peters S, Horn L, Audigier-Valette C, Pardo Aranda N,
Juan-Vidal O, Cheng Y, et al: Second-line nivolumab in relapsed
small-cell lung cancer: CheckMate 331. Ann Oncol. 32:631–641. 2021.
View Article : Google Scholar : PubMed/NCBI
|
